Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30237% above fair value
$111.60−2.62 (-2.29%)
Close on Nov 13, 2026Market cap $7.00BP/E –Yield –
Twist Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Twist Bioscience's R&D Expenses for the twelve months ending Jun 30, 2026 was $71.86M, down 14.9% year over year. For fiscal 2025 it was $80.29M, down 11.6% from the year before. The highest annual figure on record is $120.31M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $80.29M | -11.6% |
| FY2024 | Sep 30, 2024 | $90.85M | -15.0% |
| FY2023 | Sep 30, 2023 | $106.89M | -11.1% |
| FY2022 | Sep 30, 2022 | $120.31M | +74.2% |
| FY2021 | Sep 30, 2021 | $69.07M | +60.6% |
| FY2020 | Sep 30, 2020 | $43.01M | +20.5% |
| FY2019 | Sep 30, 2019 | $35.68M | +75.4% |
| FY2018 | Sep 30, 2018 | $20.35M | +6.1% |
| FY2017 | Sep 30, 2017 | $19.17M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $18.03M | -0.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $19.70M | -17.7% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $17.13M | -19.6% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $17.01M | -19.5% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $18.05M | -19.7% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $23.92M | -1.0% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $21.31M | -7.8% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $21.13M | -11.0% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $22.47M | -8.4% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $24.15M | -11.8% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $23.10M | -26.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $23.75M | -19.8% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $24.53M | -33.4% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $27.38M | -12.3% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $31.24M | +38.1% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $29.61M | +52.3% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $36.84M | +85.7% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $31.23M | +97.8% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $22.63M | +61.6% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $19.44M | +67.1% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $19.84M | +89.9% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $15.79M | +48.6% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $14.00M | +36.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $11.64M | +10.9% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $10.44M | +16.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $10.63M | +19.3% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $10.30M | +41.6% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $10.50M | +73.1% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $9.01M | +71.0% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $8.91M | +89.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $7.27M | +69.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $6.07M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $5.27M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $4.71M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $4.30M | – |
See a number that looks wrong?